Medicus Pharma (NASDAQ:MDCX) (TSXV:MDCX) announced a collaborative agreement with Swanielle to explore the expansion of its SKNJCT-003 Phase 2 clinical study for the treatment of basal cell carcinoma in the Asia-Pacific...
Revelation Biosciences (NASDAQ:REVB) announced that the FDA has accepted its investigational new drug (IND) application for Gemini in chronic kidney disease (CKD). The company notes that the milestone enables the launch...
Elite Pharmaceuticals (OTCQB:ELTP) announced it has launched a generic version of Norco tablets, a combination of hydrocodone bitartrate and acetaminophen for pain management. The generic hydrocodone bitartrate and...
Profound Medical (NASDAQ:PROF; TSX:PRN) announced a definitive co-sales and co-marketing agreement with Siemens Healthineers (XETRA:SHL) pursuant to which the companies will commercialize a new MRI-guided prostate...
CervoMed (NASDAQ:CRVO) announced that the FDA has granted orphan drug designation (ODD) to its lead investigational therapy, neflamapimod, for the treatment of frontotemporal dementia (FTD). Following the announcement...
Perimeter Medical Imaging AI (TSX-V: PINK; OTC: PYNKF) highlighted the November 26, 2024 webinar entitled, “Clearer Margins. Greater Confidence. Exploring the Benefits of OTC”, sponsored by the American Society of...
Profound Medical (NASDAQ:PROF; TSX:PRN) announced that it will unveil its third TULSA-AI software module, UA Alignment Assistant at the upcoming 110th Scientific Assembly and Annual Meeting of the Radiological Society...
MaaT Pharma (EURONEXT: MAAT) announced that its IASO Phase 1b clinical trial, evaluating the safety and tolerability of multiple doses of MaaT003 in amyotrophic lateral sclerosis (ALS), has met its primary endpoint...
IMUNON (NASDAQ: IMNN) announced the results of its end-of-Phase 2 meeting with the FDA supporting investigational interleukin-12 (IL-12) immunotherapy IMNN-001 for the treatment of advanced ovarian cancer into a 500...
Ikonisys Group (Euronext Paris:ALIKO) announced that its subsidiary, Hospitex, has been awarded a public tender to supply the innovative Ikoniscope20 robotic microscope to the Department of Pathological Anatomy in...
Enveric Biosciences (NASDAQ:ENVB) announced the completion of preclinical pharmacokinetic (PK) studies of EB-003, which support its oral bioavailability and targeted non-hallucinogenic profile. EB-003 is a potential...
BioLineRx (NASDAQ:BLRX; TASE:BLRX) and Ayrmid, the parent company of Gamida Cell, announced they have entered into a licensing agreement for motixafortide, commercially marketed in the U.S. as BioLineRx’s APHEXDA. The...
Rallybio (NASDAQ:RLYB) announced the commencement of an open-label Phase II trial of RLYB212 in pregnant women at high-risk of HPA-1a alloimmunization and fetal and neonatal alloimmune thrombocytopenia (FNAIT). FNAIT is...
Perimeter Medical Imaging AI (TSX-V:PINK) (OTC:PYNKF) announced positive topline results from the pivotal study designed to support its planned FDA PMA submission for approval to market its next-generation Perimeter B...
Neurizon Therapeutics (ASX: NUZ & NUZOA) announced positive results from a preclinical study of its lead candidate, NUZ-001, in amyotrophic lateral sclerosis (ALS). The company states that NUZ-001 reduces the...
Adverum Biotechnologies (NASDAQ:ADVM) announced topline 52-week results from its LUNA Phase 2 trial, new four-year long-term follow-up data from its OPTIC study, and key design elements for its pivotal program. Both the...
Therma Bright (TSXV:THRM; QTCQB:TBRIF) announced plans to spin off its consumer product portfolio into a separate publicly traded company during the first half of 2025. The spin-off transaction will be subject to...
AC Immune (NASDAQ:ACIU) announced positive interim safety and immunogenicity data from its Phase 2 VacSYn clinical trial, evaluating ACI-7104.056 as a treatment for patients with early Parkinson’s disease. The company...
Moleculin Biotech (NASDAQ:MBRX) announced it has amended the protocol with the FDA for its Phase 3 pivotal MIRACLE trial, evaluating Annamycin in combination with Cytarabine for treating patients with acute myeloid...
BioRestorative Therapies (NASDAQ:BRTX) announced new preliminary 26–52 week blinded data from the first 10 patients with chronic lumbar disc disease (cLDD) enrolled in the ongoing Phase 2 clinical trial of BRTX-100...
Eupraxia Pharmaceuticals (TSX:EPRX; NASDAQ:EPRX) announced positive clinical data from the fifth cohort of its RESOLVE Phase 1b/2a trial, a multi-center, open-label, dose-escalation study to evaluate the safety...
Lipella Pharmaceuticals (NASDAQ:LIPO) announced that the U.S. Patent and Trademark Office (USPTO), has issued a patent for its proprietary liposomal delivery platform today. Lipella reports that the patent protects its...